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1. Introduction
Systemic lupus erythematosus (SLE) is a complex multifactorial autoimmune disease charac‐
terized by loss of immune tolerance and defective immune regulatory mechanisms that leads
to B cell hyperactivity and the production of pathogenic autoantibodies directed against a wide
range of autoantigens, and particularly nuclear antigens [Liossis et al., 1996; Yurasov et al.,
2006; Mandik-Nayak et al., 2008]. In common, the complex interaction of genetic, environ‐
mental, as well as immunological factors causes the breaking of self-tolerance of the immune
system and leads to development of autoimmunity. The immune system has various mecha‐
nisms at the cellular and molecular level that negatively regulate immune responses and
counteract establishment of chronic and destructive immunity [Nakken et al., 2012]. A number
of circulating cytokine abnormalities have been reported in SLE and recent advances have
revealed new insights in cytokine regulation of autoimmune inflammatory responses [Diveu
et al., 2008]. In particular, the production of Interleukin-10 (IL-10) and transforming growth
factor-β1 (TGF-β1), the two main Treg cytokines that suppress the inflammatory response, has
been found to be deeply deregulated in SLE patients, so they have been considered essential
elements in the etiopathology of the disease.
Given the importance of cytokines in immune system regulation, these molecules are of high
interest not only in the “effector phase” of autoimmune disease in which self-tolerance has
already been broken, but also in the “initiation phase” of autoimmunity, in which a lasting
immune response against self antigens is first generated. Recently, it has been suggested that
initial susceptibility to autoimmune disease lies at least partly in the genetics of cytokine
regulation, and that many genetic polymorphisms affecting cytokine patterns could alter
thresholds for immune responses, resulting in pro-inflammatory presentation of self antigens
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and the subsequent misdirection of adaptive immunity against self which is observed in
autoimmune disease [Kariuki et al., 2010]
Genetic polymorphisms have emerged in recent years as important determinants of disease
susceptibility and severity. Polymorphisms are naturally occurring DNA sequence variations,
which differ from gene mutations in that they occur in the normal healthy population and have
a frequency of at least 1%. Approximately 90% of DNA polymorphisms are single nucleotide
polymorphisms (SNPs) due to single base substitutions. Others include insertion/deletion
polymorphisms, minisatellite and microsatellite polymorphisms. Although most polymor‐
phisms are functionally neutral, some have effects on regulation of gene expression or on the
function of the coded protein. These functional polymorphisms, despite being of low pene‐
trance, could contribute to the differences between individuals in susceptibility to and severity
of disease. Many studies have examined the relationship between certain cytokine gene
polymorphism, cytokine gene expression in vitro, and the susceptibility to and clinical severity
of diseases [Bidwell et al., 1999; Hollegaard and Bidwell, 2006]. Some genetic polymorphisms
at the promoter regions of IL-10 and TGF-β1 genes have been associated with cytokine
production. Given that the production of these molecules is controlled at genetic level,
functional polymorphisms in their promoters could influence the development and severity
of the disease. In the present review, we summarize the information about involvement of
IL-10 and TGF-β1 genetic variants on SLE appearance and clinical presentation.
2. Role of IL-10 and TGF-β1 in immune regulation and autoimmunity
2.1. IL-10
IL-10 is a pleiotropic cytokine with important immunoregulatory functions, which can be
produced  by  both  leukocytes  and  structural  cells  within  tissues,  being  produced  in
particular by Tregs in vivo [Wakkach et al., 2008]. It is pivotal in inhibiting inflammation
and suppresses Th1-mediated immune response through down regulation of proinflmama‐
tory cytokine secretion from both Th1 and activated macrophages (De Waal Malefyt et al.,
1993;  Fiorentino et  al.,  1998].  It  also inhibits  antigen presenting cells  by downregulating
major histocompatibility complex class II (MHC-II) and B7 expression [Ding et al., 1993].
In addition to these inhibitory actions, IL-10 promotes B-cell-mediated functions, enhanc‐
ing survival, proliferation, differentiation, and antibody production [Rousset et al.,  1992].
Hence, increased production of IL-10 could thus explain B cell hyperactivity and autoanti‐
body production,  two main features  of  the  immune dysregulation in  SLE.  In  fact,  high
serum  levels  of  IL-10  have  been  reported  in  patients  with  SLE  and  they  correlated
positively with the disease activity [Park et al., 1998].
The role of IL-10 in the pathogenesis of lupus remains controversial. The abnormally elevated
amounts of IL-10 detected in serum of patients with SLE [Houssiau et al.,1995] and the
observation that anti-IL-10 therapy can down-modulate disease in such patients [Llorente and
Riehaud-Patin, 2003] suggest that this cytokine may promote disease. In contrast, mouse
models have suggested a preventive role for IL-10 in the pathogenesis of lupus [Yin et al.,
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2002]. In particular, IL-10 knockout mice were demonstrated to develop severe lupus, with
earlier appearance of skin lesions, increased lymphadenopathy, more severe glomeruloneph‐
ritis, and higher mortality than their IL-10-intact littermate controls [Yin et al., 2002]. Interest‐
ingly, the injection of IL-10 could prevent the occurrence of the disease in such models [Yin et
al., 2002]. The authors of the study suggested that the contradictory role of IL-10 in lupus could
be explained taking into account the phase of the disease. IL-10 deficiency enhanced IFN-γ
production in the CD4 and CD8 lineages, and that, in turn, was associated with increased
production of IgG2a anti-dsDNA antibodies, especially at the early stages of disease develop‐
ment. In contrast, at later phases of disease, excessive amounts of IL-10 production led to
enhanced autoantibody production and subsequent formation of pathogenic autoantibody–
antigen complexes [Yin et al., 2002]. However, Llorente and colleagues demonstrated that
constitutive IL-10 production by monocytes and B cells in healthy members of multicase
families with SLE was significantly higher than that of healthy unrelated controls, but was
similar to that of SLE patients, thus suggesting that a genetically controlled high innate IL-10
production may predispose to SLE development. [Llorente et al.,1997]
2.2. TGF-β1
Recently, experimental studies have demonstrated an association between TGF-β1 and the
development of autoimmunity [Aoki et al., 2005]. TGF-β1 belongs to a large family of multi‐
functional proteins, secreted by a variety of cell types that act as signal molecules in controlling
a great number of biological processes. Like IL-10, it is a highly pleiotropic cytokine with an
important role in maintaining immune homeostasis [Li et al., 2006]. There are three TGF-β
isoforms in mammalian cells, TGF-β1, 2 and 3, which use similar signaling pathways and exert
overlapping, albeit not identical biological functions. TGF-β1 is involved in many critical
cellular processes, including cell growth, extracellular matrix formation, cell motility, hema‐
topoiesis, apoptosis and immune function (Moustakas et al., 2002; Schuster & Krieglstein,
2002). The cells of immune system, including B, T and dendritic cells as well as macrophages,
mostly produce TGF-β1, an isoform that is also found in large amounts in the plasma [Flanders
and Roberts, 2001]. TGF-β1 has pronounced anti-inflammatory and immunosuppressive
functions, the latter being realized by controlling the activation, proliferation, differentiation
and survival of all effector immune cells [Rubtsov et al., 2007; Wahl, 1992]. Importantly, TGF-
β1 inhibits maturation of dendritic cells and modulates the functions of antigen-presenting
cells, reducing the macrophage production of IL-1, IL-6, and TNF-α [Fainaru et al., 2007].
However, immunosuppressive effect of TGF-β1 was most pronounced for T cells [Rubtsov et
al., 2007; Li et al., 2006]. It inhibits T cell proliferation and production of IL-2, differentiation
of Th1, Th2, and cytotoxic T lymphocytes (CTL). TGF-β1 suppresses IFN-γ production from
Th1, NK cells and CTL, as well as their cytotoxic activity. TGF-β1 plays an essential role in the
functioning and survival of regulatory T cells (Treg), and de novo generation of Foxp3+ Treg
from naive CD4+ CD25- T lymphocytes in the periphery [Pyzik et al., 2007; Selvaraj et al.,
2007; Zheng et al., 2007]. Furthermore, recent study reveals a role for TGF-β1 as effector
molecule of Foxp3+ Treg cells [Li et al., 2007]. In contrast to IL-10, TGF-β1 is also an important
negative regulator of B cell differentiation and proliferation, inhibiting the production of most
immunoglobulin isotypes except IgA [Lebman and Edmiston, 1999].
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There are strong evidences to suggest the great importance of this cytokine in the control of
autoimmunity [Aoki et al., 2005]. An association between TGF-β1 and the development of
autoimmunity is clearly demonstrated in studies with complete knockout of TGF-β1 in mice
or genetic manipulation of its receptors in T cells. TGF-β1 knockout mice and those with
impaired TGF-β1 signaling in T cells develop an autoimmune syndrome with multiple organ
involvement and death [Shull et al., 1992; Dang et al., 1995; Gorelik et al., 2000; Marie et al.,
2006;]. This syndrome resembles SLE and Sjogren's syndrome in humans [Dang et al., 1995]
and is characterized by multifocal inflammatory process affecting the heart, brain, lungs,
skeletal muscle, liver, stomach, pancreas, salivary glands and other organs, lymfoproliferation,
spontaneous activation of autoreactive T lymphocytes and production of autoantibodies
[Dang et al., 1995; Shull et al., 1992].
3. Functional IL-10 and TGF-β1 genetic polymorphisms
3.1. IL-10 genetic polymorphisms and IL-10 production
Human IL-10 is secreted mostly by antigen-presenting cells and Treg lymphocytes subset in
response to several activation stimuli. This cytokine could be also constitutively produced at low
levels by immune cells, mainly monocytes, macrophages and dendritic cells. IL-10 is a non-
covalent homodimer of 36 kDa with two polypeptide chains and its gene, with GeneBank
accession number: X78437, is located on chromosome 1 at 1q31- q32 and a number of polymor‐
phisms in the promoter region have been characterized. In contrast to many other cytokines, the
synthesis of IL-10 is regulated by the transcription factors Sp1 and Sp3, which are constitutive‐
ly expressed by different cell types [Moore et al. 2001]. It has been recently shown that c-Jun binds
to a highly conserved noncoding sequences (CNS-3) in the IL10 locus, enhancing the expres‐
sion of IL-10, and AP-1 signaling pathway particularly through c-jun transcription and activity
strongly affects IL-10 expression in the Th2 cells and monocytes [Wang Z et al., 2005; Dobreva et
al., 2009]. Large interindividual differences in the IL-10 inducibility have been observed, which
has shown to have a genetic component of over 70%. The IL-10 gene comprises 5 exons, and to
date, at least 49 IL10–associated polymorphisms have been reported, and an even larger number
of polymorphisms are recorded in SNP databases (Ensembl Genome Browser, 2006). Promoter
polymorphisms have been subject to the most studies, particularly with regard to possible
influences on gene transcription and protein production. Three SNPs at -1082(A/G), -819(C/T),
-592(C/A) upstream from the transcription start site [D'Alfonso et al., 1995; Turner et al., 1997]
have been described as well as additional two microsatellite (CA)n repeats, termed IL10.G
(-1.1Kb) and IL10.R (-4Kb) and located at -1151 and -3978 respectively (Eskdale and Galager, 1995;
Eskdale et al., 1997).
A complete  linkage disequilibrium exists  between the  alleles  present  at  positions  -1082,
-819  and  -592;  so  these  polymorphisms  occurred  in  tandem  These  SNPs  have  been
associated with variability in IL-10 production [Eskdale et al., 1998; Turner et al., 1998]. In
particular, SNP at position -1082A/G of IL-10 gene has been associated with IL-10 produc‐
tion alone  or  in  haplotypes  with  other  distal  SNPs.  Turner  et  al.,1997  have  shown that
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-1082A allele is associated with lower in vitro IL-10 production by Con A-stimulated PBMC
from normal subjects. In our studies, the functional effect of -1082 A/G polymorphism was
demonstrated among the Bulgarian population in both healthy volunteers and in patients
with sepsis (Stanilova et al., 2006). In Caucasian populations, only three haplotypes have
been  found  (GCC,  ACC  and  ATA),  the  individuals  GCC/GCC  being  considered  as
genetically high IL-10 producers [Suarez et al., 2005; Suarez et al., 2003; Turner et al., 1997].
Although  the  functional  effects  of  polymorphisms  in  IL-10  have  not  yet  been  fully
elucidated,  obviously that  they may play a  significant  role  in  modulating susceptibility,
development  and  clinical  fetures  of  autoimmune  disease  and  particularly  SLE.  The
observation of increased circulating levels of IL-10 in active SLE patients which revealed
positive correlation with SLEDAI and anti-double-stranded DNA (dsDNA) titer has been
reported (Park et al., 1998; Hye-Young et al., 2007). Moreover, a trend toward SLE patients
having hypomethylated IL-10 promoter region accompanied by greater disease activity of
SLE was recently observed (Lin et al., 2012).
3.2. TGF-β1 genetic polymorphisms and plasma concentrations of TGF-β1
The  TGF-β1  gene  is  located  on  chromosome  19  (q13.1-13.3)  and  several  SNPs  were
described so far in promoter region, in the non-translated region (introns), in the coding
region (exons), and in the 3’-UTR region of the gene. They include three polymorphisms
in the promoter region (-988C/A, -800G/A, and -509C/T),  two polymorphisms located in
exon 1 +869T/C (codon 10) and +915G/C (codon 25), one on exon 5 +11929C/T (codon 263),
and  one  in  3’-UTR  region  of  the  gene  at  position  +72  [Cambien  et  al.,  1996].  Certain
inherited variants in the promoter region of the TGF-β gene (-800G/A and -509C/T) have
been  associated  with  higher  cytokine  circulating  concentrations.  The  -800G/A  SNP  is
located in a consensus cyclic AMP response element binding protein (CREB) half site and
may cause reduced affinity for CREB transcription factors whose binding is important for
transcription control [Grainger at  al.  1999].  The -509C/T is located within a YY1 consen‐
sus binding site and -509T allele has been associated with increased TGF-β1 plasma level
[Grainger at al. 1999] and reduced T-cell proliferation [Meng et al.,  2005] and a study of
twins estimated that the -509C/T polymorphism explained approximately 8% of the genetic
variation in TGF-β1 plasma levels (Grainger at al.,1999). Two SNPs, the +868T/C SNP, and
the +915G/C SNP, give rise to amino acid substitutions at positions 10 (Leu10Pro) and 25
(Arg25Pro) in the signal peptide of TGF-β1, respectively (Cambien et al.,1996; Awad et al.
1998).  The +868T/C SNP was reported to influence steady-state concentrations of  TGFB1
mRNA in peripheral blood mononuclear cells and serum levels of TGF-β1, and the +915G/
C SNP was found to be related to TGF-β1 production in peripheral blood leukocytes (Awad
et  al.,  1998).  Another  nonsynonymous  SNP  of  TGFB1,  the  +11929C/T  SNP  (Thr263Ile)  is
located in  exon 5  (Cambien et  al.,1996;  Awad et  al.1998).  The  11929C/T SNP is  located
closely to the site where the latency-associated peptide is cleaved from the active part of
the protein (Dubois et al.,  1995) and therefore, this SNP may be related to the activation
process of TGF-β1, as suggested previously (Cambien et al. 1996). A high degree of linkage
disequilibrium was observed between pairs of the −509C/T, 868T/C, 913G/C, and 11929C/T
SNPs in white populations (Cambien et al.,1996; Grainger at al. 1999).
Gene Polymorphisms of Immunoregulatory Cytokines IL-10 and TGF-β1 in Systemic Lupus Erythematosus
http://dx.doi.org/10.5772/53799
37
Although immunosuppressive effects of TGF-β1 have been well established, few studies have
investigated serum TGF-β1 levels in autoimmune disorders. In fact, patient with SLE have
reduced TGF-β1 production by their peripheral blood lymphocytes (Oshtuka et al., 1998).
Hence, reduced TGF-β1 production by immune cells might contribute to the characteristic T
cell disregulation, aberrant stimulation of autoreactive B cell, and autoantibody production in
SLE patients. Also, it has been reported that decreased serum levels of TGF-β1 in patients with
systemic lupus are the most pronounced and constant abnormality in the cytokine levels in
these patients [Becker-Merok et al., 2010]. In attempt to elucidate the importance of TGF-β1
for the development of SLE we measured serum levels of TGF-β1 in 53 patients with SLE
recruited from ‘St Ivan Rilski’ University Hospital, Sofia and in 66 healthy controls [unpub‐
lished data]. Serum samples were routinely collected and stored frozen at -20 C until assayed.
At the time of sampling, neither of the patients and control subjects had clinical signs or
symptoms of intercurrent illness. The concentrations of activated TGF-β1 protein in the serum
samples of patients and controls were measured by quantitative sandwich ELISA technique,
using commercially available kits (Qantakine®, R&D systems, Abingdon, UK). Before assay,
the latent TGF-β1 contained in sera was activated to the immunoreactive form using acid
activation and neutralization. The results were calculated by reference to the standard curve
and expressed as ng/ml. Table 1 presents the serum concentrations of TGF-β1 in patients and
healthy controls.
TGF-β1 concentrations (mean±SD) Significance
SLE
total (n=53) 8.88 ± 3.79
male (n=7) 8.57 ± 2.72
female (n=46) 8.93 ± 3.95 male vs female p = 0.82
Healthy controls
total (n=66) 32.99 ± 24.84
male (n=13) 60.98 ± 31.32
female (n=53) 26.12 ± 17.34 male vs female p <0.001
Significance SLE vs HC p<0.001
Table 1. TGF-β1 concentrations (ng/ml 9) in SLE patients and healthy controls.
Our results showed significantly lower levels of active TGF-β1 in lupus patients compared
with healthy individuals (p<0.001). These data are in principal agreement with other studies
[Jin et al., 2011; Lu et al., 2004]. In addition to the decreased TGF-β1 serum concentrations in
SLE patients, the authors of these studies also reported an association between lower TGF-β1
and disease activity, as well as the development of organ damage [Jin et al., 2011; Lu et al.,
2004]. Taken together, these observations support the role of TGF-β1 in SLE pathogenesis and
modulation of disease expression. In our study, we also observed a large interindividual
Genes and Autoimmunity - Intracellular Signaling and Microbiome Contribution38
variation in serum TGF-β1 levels among healthy subjects. This variation might be partly due
to the possible influence of some endogenous factors, such as gender and age on the production
of TGF-β1. Given this supposition, we examined TGF-β1 levels in the context of age and gender
in both healthy and affected individuals. The highest levels of TGF-β1 were found in men
among the healthy subjects. In SLE patients such a correlation between serum levels of TGF-
β1 and gender was not observed (Table 1), which could be explained with fact, that only men
individuals with genetic predisposition to lower TGF-β1 production developed SLE or down
regulation of TGF-β1 by disease progress. Additionally, age was positively correlated with
serum TGF-β1 in healthy controls. TGF-β1 serum levels were lower in individuals under 45
years and higher in those aged over 45 years (P<0.001) among healthy controls as shown in
Figure 1. In SLE patients, there was not a relationship between age and serum TGF-β1 levels.
Thus, healthy individuals showed a pattern in which serum TGF-β1 was higher in men and
elder people. It seems likely that age- or gender-specific cytokine differences could play a role
in the observed age- and gender-related incidence patterns observed in SLE [Petri M,
2002].These data allow us to hypothesis that high levels of serum TGF-β1 may protect against
autoimmunity in men as well as low levels of serum TGF-β1 may predispose to the onset of
autoimmunity in younger individuals.
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Figure 1. Mean (±SD) serum TGF-β1 concentrations (pg/ml) in SLE patients and healthy controls according to the age
of individuals.
Nowadays, it is considered that the control of TGF-β1 production is complex, but it has been
estimated that 54% of its production is under genetic control [Grainger et al., 1999]. In this
regard, we analyzed the serum levels of TGF-β1 in relation to various genotypes of -509C/T
polymorphism of TGFB1 in 52 healthy controls (n = 21 for CC, 15 for CT, and16 for TT) and in
48 SLE patients (n = 17 for CC, 24 for CT, and 7 for TT). As the mean TGF-β1 levels varied
significantly by case-control status (P < 0.001), patients and controls were proceeded separetly
for the genotype-serum levels analysis. The results are presented on Figure 2. Among healthy
individuals the highest TGF-β1 concentration was detected in individuals with TT genotype
(mean ± SD, 56.9 ± 28.6 ng/ml) compared to those with CC genotype (mean ± SD, 29.5 ± 21.1
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ng/ml; p = 0.001) and those with CT genotype (mean ± SD, 25.7 ± 18.8; p = 0.002). Besides the
level of serum TGF-β1 in patients was found to be lower than in control subjects (Figure 1),
significantly higher TGF-β1 levels were observed in SLE patients having the TT genotype
(mean ± SD, 9.8 ± 2.6 ng/ml) compared to patients with CC genotype (mean ± SD, 6.7 ± 2.6 ng/
ml; p=0.023). Overall, individuals with TT homozygous genotype had higher serum TGF-β1
concentration in comparison to those with either CC homozygous genotype or CT heterozy‐
gous genotype.
The study of Awad and colleagues related the carriage of GG homozygous genotype in
position +915 of TGFB1 to significantly higher TGF-β1 production in peripheral blood
leukocytes [Awad et al., 1998]. However, Lu et al., 2004 also, analyzing the serum levels of
TGF-β1 as well as the TGF-β1 production of unstimulated and stimulated peripheral blood
mononuclear cells, did not observe functional correlations with TGF-β1 production and -509
and codon10 alleles. The authors raise the question whether the lower serum TGF-β1 level that
cause defective immune regulation in SLE is primarily under genetic control or secondary to
the influence of ongoing cellular interactions in the cytokine context. The data from our
preliminary study shown that a number of factors such as age, sex, presence of disease, and
allele variants of -509 C/T SNP in the gene for TGF-β1 influence the level of this cytokine in
the serum. Thus, a genetically controlled low production of TGF-β1 is a predisposing factor
for the loss of negative regulation found in SLE and may constitute an important component
of the genetically determined susceptibility to this disease and the autoimmune events
responsible for its pathogenesis, developed under appropriate environmental stimuli.
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Figure 2. Mean (± SD) serum TGF-β1 concentrations (ng/ml) in SLE patients and healthy controls according to the gen‐
otypes of -509 C/T polymorphism of TGFB1. * p < 0.05, ** p <.01
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4. Role of IL-10 and TGF-β1 genotypes as risk factor for appearance of SLE
4.1. Role of IL-10 promoter polymorphism in susceptibility and clinical manifestation of
SLE
Several evidences suggest that IL-10 could be a strong candidate gene influencing SLE
susceptibility. IL-10 gene has been mapped to chromosome 1q31-32, which is a susceptibility
region for SLE (LOD=3.79) [Johanneson et al., 2002]. It is also homologous to a murine SLE
susceptibility region [Tsao et al., 1997]. More recently, Gateva et al., 2010 performed a large-
scale replication study involving 1,310 cases and 7,859 controls, and identified 21 additional
candidate susceptibility loci for SLE. Among the newly identified SLE loci is IL-10.
However, in spite of the considerable number of genetic studies performed, no definitive result
about its involvement in SLE susceptibility was achieved. Some works showed significant
associations between IL-10 microsatellites or SNPs with SLE susceptibility or with the
development of certain clinical or immunological features [Rood et al., 1999; D’Alfonso et al.,
2002; Schotte et al., 2004; Chen et al., 2006; Sung et al., 2006; Chong et al., 2006; Rosado et al.,
2008] while other studies indicated that these polymorphisms did not appear to have any
relevance in the disease [Alarcón-Riquelme et al., 1999; Van der Linden et al., 2000; Dijstel‐
bloem et al., 2002; Guarnizo-Zuccardi et al., 2007]. The role of IL-10 genotypes has been recently
reviewed by Lopez et al., 2010. The more recent association studies dealing IL-10 promoter
polymorphisms for SLE susceptibility are summarized on Table 2.
With respect to microsatellite variants, different alleles of IL10.G have been reported to be
associated with SLE incidence in various populations. Thus, frequency of IL10.G9 allele (21
CA repeats) was significantly decreased in European [D’Alfonso et al., 2000, D’Alfonso et al.,
2002, Eskdale et al., 1997] and Mexican-American [Mehrian et al., 1998] SLE patients, whereas
the long alleles IL10.G10, G11 and G13 (with a CA repeat number greater than 21) were
significantly increased in Mexican-American [Mehrian et al., 1998], Italian [D’Alfonso et al.,
2000, D’Alfonso et al., 2002] and British [Eskdale et al., 1997] patients respectively. On the
contrary, an increase in IL10.G4 (short allele) was reported in Chinese patients [Chong et al.,
2004] whereas no significant differences in IL10.G alleles were detected in other cohorts
[Schotte et al., 2004, Alarcon-Riquelme et al., 1999; Johansson et al., 2002]. Recently, a large
meta-analysis summarized the results focused on the role of IL-10 promoter polymorphisms
for SLE susceptibility from 16 published case-control studies involving a total of 2391 SLE
patients and 3483 controls (Nath et al., 2005). The results of the meta-analysis performed by
Nath et al., 2005 showed a significant association between SLE and the G11 allele of IL10.G
(OR=1.279, 95% CI; 1.027±1.593, P=0.028) in whole populations, and IL-10 promoter -1082G
allele was associated with SLE in Asians (OR=1.358, 95% CI; 1.015±1.816, P=0.039). It has been
reported that LPS-stimulated cells from individuals carriers of the IL10.G allele with 26 CA
repeats presented higher IL-10 production than those from carriers of short alleles [Eskdale et
al., 1998], suggesting that long alleles might be responsible for a high IL-10 production. Thus,
accordingly to these data, high IL-10 producer genotypes (with more than 21 CA repeats) could
be associated with SLE susceptibility, while presence of short alleles could confer a protective
effect [Chen et al., 2006; D’Alfonso et al., 2002].
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Polymoprhisms Association SLE/contr. Population References
IL10G, IL10R
-1082; -819; -592
Association of IL10.G11 allele in
whole populations;
Association of -1082G allele with
SLE in Asians
2391/3483 Meta-analysis Nath et al., 2005
-592 A/C
No association with susceptibility
Association of -592C with SLE
activity
350/330 Korean Sung et al., 2005
IL10G
Increased G9 and decreased G8 in
SLE
Association of G13 with ACLA-IgM
Association of G8 with CNS lupus
237/304 Taiwanese Chen et al., 2006
-1082, -819, -592 Association of ACC/ACC withsusceptibility to SLE 195/159 Thai
Hirankarn et al.,
2006
-1082; -819; -592 No association 120/102 Colombian Guarnizo-Zuccardiet al., 2007
IL10G, IL10R
-1082; -819; -592
No association of microsatellites
Increased GCC in SLE 116/51 Spanish Rosado et al., 2008
-1082; -819; -592 Increased GCC in SLE 103/300 Polish Sobkowiak et al.,2009
-1082; -819; -592
-592 A/C No association 110/138 Chinese Yu et al., 2010
-1082; -819; -592 Increased ATA haplotype in sLE 172/215 Taiwanese Lin et al., 2010
-1082 No association 157/126 Bulgarian Miteva et al., 2010
Table 2. Association of IL-10 promotor polymorphisms - IL10G, IL10R, -1082G/A (rs1800896), -819C/T (rs1800871),
-592A/C (rs1800872), with SLE. Association studies published after 2005 years are given only.
Conflicting results were also obtained after examining the possible association between SLE
susceptibility and SNPs at -1082, -819, and -592 positions of IL-10 gene in the different
populations in which they were investigated. The frequency of high IL-10 producers (carriers
of -1082G allele or GCC haplotype) has been found to be increased in several works with Asian
[Nath et al., 2005; Hirankarn et al., 2006] or European [Rosado o et al., 2008; Sobkowiak et al.,
2009] patients, although most of the studies performed in Caucasian populations did not show
significant associations [Lazarus et al. 1997, Guarnizo-Zuccardi et al, 2007;, Koss et al., 2000;
Suárez et al., 2005; Dijstelbloem et al., 2002; Van der Linden et al., 2000; Crawley et al., 1999].
Rosado et al., 2008 found that the GCC haplotype frequency was significantly higher in Spanish
patients with SLE. To assess the functional role of genotypes, they also quantified serum IL-10
levels from patients and controls and found higher serum IL-10 levels in patients. On the basis
of these data, they suggest that the IL-10 promoter haplotype that produces higher levels of
cytokine is associated with SLE in Spanish population. Similar are the results and final
conclusion of the study performed by Sobkowiak et al., 2009; despite the higher prevalence of
the GCC/GCC, GCC/ATA and ATA/ATA genotypes in SLE patients than in controls, they
Genes and Autoimmunity - Intracellular Signaling and Microbiome Contribution42
observed that only GCC/GCC genotype was significant more frequent in SLE. Hence, the
conclusion suggests the GCC/GCC promoter genotype may contribute to SLE incidence in
Polish patients. A very recent study investigated the association between of IL-10 promoter
polymorphisms (-1082, -819 and -592) with SLE in a total of 172 Taiwanese patients and 215
controls reported an association of IL-10 ATA haplotype with SLE in Taiwanese population
[Lin et al., 2010]. In another Asian population, an association of ACC/ACC haplotype of IL-10
in susceptibility to SLE has been observed by Hirankarn et al., 2006.
In this regard, we investigated the role of -1082A/G promoter polymorphism of IL-10 gene as risk
factor for development and clinical manifestations of SLE in Bulgarian population. Our prelimi‐
nary results did not reveal a significant association of -1082 SNP in IL-10 with SLE [Miteva et al.,
2010]. New data for the distribution and the frequencies of the -1082A/G alleles and genotypes
among the SLE patients and healthy controls are presented on Table 3. The results of our case-
control study based on 157 patients with SLE and 166 unaffected control individuals showed that
the genotype distribution is consistent with those published for other Caucasian type control
cohorts [Lopez et al., 2010). We also found the prevalence of homozygous GG genotype in SLE
cases (27%) compared to the controls (13%) with OR = 1.185 (95% CI = 0.58÷2.45), although the
difference did not reach statistical significance (p=0.548). In addition, we observed an in‐
creased frequency of GG genotype compared to the reference AA genotype in patients with
antiphospholipid synrom (APS) (27%) compared with patients without APS (14%) with OR =
2.750, 95% CI = 0.910 ÷ 8.347, p = 0.074). This suggests that carriage of a higher IL-10 producing
genotype is a risk factor for antiphospholipid autoantibody production and APS appearance,
thus having a modifying effect on the clinical presentation of the disease.
rs1800896-10
82 A/G
IL10
Genotype Allele
AA
n (%)
AG
n (%)
AG+AA
n (%)
AG+GG
n (%)
GG
n (%)
A
n (%)
G
n (%)
SLE (n=157)
56 74 130 101 27 186 128
(36%) (47%) (73%) (74%) (27%) (59%) (41%)
χ2 =0.203
HC (n=166)
59 83 142 107 24
p=0.934
201 131
(36%) (50%) (86%) (64%) (14%) (61%) (39%)
OR
(95% CI)
0.844 0.793 0.814 1 0.947 1
(0.41±1.72) (0.40±1.56) (0.43±1.54) - ref. (0.68±1.31) ref.
p 0.614 0.471 0.5 - 0.735
OR
(95% CI)
1. 0.939 - 0.994 1.185 1 1.056
ref (0.56±1.57) (0.61±1.61) (0.58±2.42) ref. (0.76±1.47)
p 0.799 - 0.981 0.614 0.735
Table 3. Genotypic and allelic frequency of gene polymorphism at position -1082 A/G in IL-10 gene in SLE patients
and controls
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The presence of autoantibodies, mainly directed against nuclear antigens (ANAs), is one
of the most characteristic features of SLE. The effect of IL-10 genotypes did not seem to
be especially relevant, although it has been reported an increased prevalence of antibod‐
ies  against  several  extractable  nuclear  antigens  (anti-ENA)  in  patients  with  the  allele
IL-10.G9 [Eskdale, et al., 1997], and the presence of anti-Sm antibodies was found signifi‐
cantly overrepresented among patient carriers of G14 and G15 alleles and R2-G15 and R2-
G14 haplotypes [Schotte et al., 2004]. An association of the carriage of low IL-10 producer
alleles  such  as  IL10.G13  allele  with  the  presence  of  anticardiolipin  IgM  antibodies  and
IL10.G8 allele with neurological affectation has been reported in Taiwanese patients with
SLE [Chen et al., 2006], results very similar to the data from our study.
Considering increased circulating levels of IL-10 have been consistently reported in the sera
of patients with SLE, it is possible that different cytokine production may not only influence
the autoantibody production,  but  also the clinical  presentation of  the disease.  However,
there  were  no  definitive  data  on  the  association  of  IL-10  polymorphisms  and  specific
clinical manifestations, probably due to the heterogeneity of the disease. For instance, renal
involvement has been associated with both high (GCC) [Lazarus et  al.,  1997,  Zhu et al.,
2005]  and  low (ATA)  [Mok et  al.,  1999]  IL-10  producer  genotypes.  High  prevalence  of
neuropsychiatric [Rood et al., 1999; Chen et al. 2006] and cardiovascular disorders [Fei et
al.,  2004] has been reported in patients with low genetic production whereas high IL-10
production has been linked to an increased incidence of serositis, hematological disorder
[Chong et al.],  SLICC/ACR Damage Index [Sung et al.,  2006] and presence of discoid or
mucocutaneous  lesions  [Suárez  et  al.,  2005;  Alarcón-Riquelme  et  al.,1999].  This  last
association was supported by the increased frequency of the high producer -1082G allele
observed in patients with discoid lupus erythematosus [Suárez et al., 2005; Van der Linden
et al., 2000] and by the fact that cutaneous manifestations improved in SLE patients under
anti  IL-10  monoclonal  antibody  treatment  [Llorente  et  al.,  2000].  In  conclusion  IL-10
promoter SNPs alone have not exhibits strong association with SLE susceptibility, but their
role  cant’  be  excluded.  Each  polymorphism  in  regulatory  regions  of  gene,  may  either
directly  influence  gene  expression  or  indirectly  via  tight  linkage  with  other  polymor‐
phisms occurring elsewhere in the same or in other cytokine gene. A particular combina‐
tion of SNPs on cytokine genes in individual genotype has different impacts on induced
cytokine production. Miteva and Stanilova investigate the combined effect of -1082A*G in
IL10  and  +16974A*C  in  IL12B  SNPs  on  induced  cytokine  production  by  stimulated
peripheral blood mononuclear cells isolated from healthy donors (Miteva, Stanilova, 2008).
Results  demonstrated  that  the  production  of  IL-10  from  PBMC  depended  on  both,
-1082А*G  in  IL10  and  +16974A*C  in  IL12B  polymorphisms  and  the  presence  of  high
producer IL-12p40 genotype led to diminished production of IL-10 determined by -1082*G-
allele of SNP in IL10. In the same vein, we suppose that individuals with genotype which
combine  SNPs  responsible  for  higher  production  of  IL-10  simultaneously  with  lower
production of TGF-β1 should be more susceptible to SLE.
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4.2. Role of TGB-β1 genetic polymorphisms in susceptibility and clinical manifestation of
SLE
Regarding the association between decreased TGF-β1 serum levels and the development of
autoimmunity, the mechanisms which control the concentration of TGF-β1 in plasma are under
extensive investigations. The concentration of both latent complex and active TGF-β1 in plasma
has been shown to be predominantly under genetic control [Grainger et al., 1999]. In light of
these findings TGF-β1 gene is a functional candidate gene for genetic predisposition in
systemic lupus erythematosus.
The presence of polymorphisms in the TGFB1 locus may indicate predisposition to diseases,
such as systemic lupus erythematosus that have been linked here and elsewhere [Caserta et
al., 2004; Lu et al., 2004] to the circulating levels of TGF-β1. To test this hypothesis, we
performed a population based case-control study to investigate the association of -509C/T
polymorphism of the TGFB1 gene with susceptibility to SLE [Manolova et al., 2012]. In this
investigation, the change at position -509C/T in the TGFB1 gene (rs1800469) was studied using
RFLP-PCR among 147 cases with SLE and 134 normal Bulgarian subjects. The genotype
distribution and allele frequencies of -509C/T SNP in gene promoter of TGFB1 among SLE
patients and healthy donors are presented in Table 4.
rs1800469
-509C/T
TGFB1
Genotype Allele
CC
n (%)
CT
n (%)
CT+CC
n (%)
CT+TT
n (%)
TT
n (%)
C
n (%)
T
n (%)
SLE (n=149)
48 79 127 101 22 175 123
(32.2%) (53%) (85.2%) (67.8%) (14.8%))
χ2=3.735
p=0.155
(58.7%) (41.3%)
HC (n=134)
48 57 105 86 29 153 115
(35.8%) (42.5%) (78.3%) (64.1%) (21.6%) (57.1%) (42.9%)
OR
(95% CI)
1.318 1.827 1.59
-
1 1.069 1
(0.63-2.77) (0.91±3.69) (0.83±3.07) ref. (0.76±1.5) ref.
p 0.428 0.068 0.133 - 0.694
OR
(95% CI)
1 1.386 - 1.17 0.759 1 0.935
ref. (0.79±2.43) (0.7±1.98) (0.36±1.59) ref. (0.66±1.33)
p 0.223 - 0.522 0.428 0.694
Table 4. Genotypic and allelic frequency of gene polymorphism at position -509 in TGFB1 gene in SLE patients and
controls
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The genotype distribution for TGFB1 -509C/T polymorphism was in agreement with Hardy-
Weinberg equilibrium among cases (χ2=2.00; p=0.367) and controls (χ2=2.237; p=0.326).
Homozygous CC genotype was found in 32.2% of patients and 36.8% of control subjects,
heterozygous CT genotype was observed in 53% of SLE patients and 42.5% of controls,
homozygous TT genotype was detected in 14.8% of cases and 21.6% of controls. There were
no significant differences in the genotype (p=0.155) and allele (p=0.694) frequencies of
-509C/T polymorphism of the TGFB1 gene between SLE patients and controls. However, we
observed a higher frequency of heterozygous CT genotype (OR = 1.827; 95% CI 0.91±3.69; p =
0.068) and lower frequency of TT genotype (OR = 0,759; 95% CI: 0.36±1.59; p=0.428) in SLE
patients compared to healthy controls. In logistic regression analysis the presence of allele C
in the genotype (CT + CC versus TT) was associated with a 1.6 times higher risk of developing
systemic lupus erythematosus.
Genotype and allele frequencies of -509C/T polymorphism in TGFB1  which we establish‐
ed in Bulgarian population were comparable to those found in other populations. Howev‐
er,  the  available  data  in  the  literature  reveal  the  existence  of  ethnic  differences  in
frequencies of  the allele  variants of  this  polymorphic marker (Table 5).  C allele had the
higher representation among Europeans in French [Cambien et al., 1996], German [Wu et
al., 2008] and British [Awad et al., 1998] studies with a frequency of 65 to 76 percent, while
among healthy individuals from different Asian ethnicities T allele occurs more frequent‐
ly or almost equally with the C allele [Amirghofran Z, 2009; Zhang et al., 2009; Chung et
al.,, 2007]. In Bulgarian population allele C is slightly more common and was found in 57%
of healthy subjects and in 59% of cases with SLE.
Locus Allele
Frequency (%) among healthy controls
Bulgarian study
Data from this
study
French study
Cambien et al.,
1996
British study
Awad et al.,
1998
German study
Wu et al., 2009
Asian study
Lu et al., 2004
-509 С 57 66 76 70 48
Т 43 34 24 30 52
Table 5. Interethnic differences in allele frequencies of -509C/T SNP in TGFB1 in healthy controls.
According to our knowledge there are only a limited number of studies aiming to evaluate the
possible role of polymorphisms in the TGF-β1 gene as predisposing factors for SLE, but the
results of these studies are contradictory. The polymorphisms in of -509C/T SNP in TGF-β1
have been explored in SLE only by three research teams [Lu et al., 2004; Caserta et al., 2004;
Vuong et al., 2010]. In overall, the contradictory results in the literature could be explained by
the genetic heterogeneity of SLE in different populations and possible sample stratification.
Table 6 summarizes the association studies dealing TGF-β1 gene polymorphisms for SLE
susceptibility.
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Polymoprhisms Association SLE/contr. Population References
+915G/C (rs1800471) No association 203/158 German Schotte et al., 2003
-988C/A (rs2241712),
-800G/A (rs1982072),
-509C/T (rs1800469),
+869T/C (rs1982073),
+915G/C (rs1800471)
No association 138/182 Taiwanese Lu et al., 2004
-509C/T (rs1800469) No association 23/32 North
America
Caserta et al., 2004
+869T/C (rs1982073),
+915G/C (rs1800471)
Association of +869C allele with
SLE; decreased high TGF-β1
producers haplotypes in SLE
(codon10 T allele/25 G allele)
No association with clinical
manifestations
120/102 Colombian Guarnizo-Zuccardi et
al., 2007
+869T/C (rs1982073) No association with susceptibility
+869TT associated with aseptic
necrosis and anti-Ro antibodies
196/102 Japan Wang et al., 2007
-509C/T (rs1800469)
+869T/C (rs1982073)
intron G/T (rs2241715)
3’-UTR A/G (rs6957)
No association 272/307 Sweden Vuong et al., 2010
-509C/T (rs1800469) Decreased frequency of TT
(OR = 0,759; 95% CI: 0.36±1.59)
allele C (CT+CC vs TT) risk factor
for SLE (OR=1.59;
95% CI: 0.83±3.07)
149/134 Bulgarian Manolova et al. 2012
Table 6. Association of TGF-β1 gene polymorphisms with SLE.
Lu et al. conducted a case-control study involving 134 patients and 182 healthy individuals of
Taiwanese origin to evaluate the association of -509C/T SNP in TGFB1 with susceptibility to
systemic lupus erythematosus [Lu et al., 2004]. In the same study, authors investigated also
association of some others TGFβ1 single nucleotide polymorphisms, including -988C/A,
-800G/A, +869T/C (Leu10Pro), and +915 G/C (Arg25Pro) with susceptibility to SLE and shown
that none of the TGFβ1 SNPs was strongly associated with SLE in Taiwanese patients. They
conclude that these polymorphisms do not represent a genetic predisposition to SLE. In
another study, Schotte and colleagues investigated the +915G/C polymorphism at codon25
and did not found any association between this polymorphism and SLE in German population
[Schotte et al., 2003]. In addition, authors found no association of major disease manifestations
or specific autoantibodies with TGFB1 genotypes or alleles. The authors conclude that +915G/
C polymorphism in TGFB1 neither significantly contributes to the disease susceptibility, nor
predisposes to clinical and immunological manifestations typical of SLE. Also, there were no
significant associations between several SNPs from the TGFβ1 including -509C/T, +869T/C,
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intronic G/T (rs2241715), and3’-UTR A/G(rs6957) with SLE or with lupus nephritis in Sweden
population [Vuong et al., 2010].
In  contrast  to  these  data  are  the  results  obtained  by  Guarnizo-Zuccardi  et  al.,  2007  for
several cytokine gene polymorphisms in Colombian patients with SLE. They analyze the
relation between the +868T/C and the +915G/C SNP in TGFB1 with the development and
clinical manifestations of SLE. The authors found a strong association of SLE with the TGF-
β1 codon25 C allele, associated with decreased TGF-β1 production and found lower rates
of higher-producing GG genotype and a higher frequency of heterozygous genotypes in
this  polymorphic  marker  in  patients  with  SLE.  As  for  the  +868T/C  polymorphism  at
codon10,  Guarnizo-Zuccardi  et  al.,  2007  did  not  observe  association  between  SLE  and
codon10 when analyzing independently, but they found a significant association when the
haplotypes codon10/20 were evaluated, which could be because of the linkage disequilibri‐
um between the two SNPs. This extended genotypic analysis revealed a lower frequency
of  high  TGF-β1  producers  –  haplotype  10/25  T/T-G/G in  Colombian  patients  with  SLE.
Unlike  the  relationship  of  +868T/C  and  +915G/C  SNPs  of  the  TGFB1  gene  to  disease
susceptibility,  they found no association between clinical features of the disease and the
polymorphisms studied. As opposed to this report, Wang et al., 2007 did not find an impact
of  +869T/C polymorphism in TGF-β1 gene on disease susceptibility  in  population-based
case-control  study  involving  196  patients  with  SLE  and  106  healthy  controls  in  Japan.
However, they found an association between +869T/C TGFB1  polymorphism and several
clinical features of SLE. The carriage of TT genotype of +869T/C polymorphism which is
associated  with  a  lower  serum  TGF-β1  level  was  related  to  the  occurrence  of  aseptic
necrosis and higher incidence of anti-SSA/Ro antibodies in SLE patients. Consistent with
the  last  finding,  the  children  with  the  TT +869T/C genotype  of  TGFB1  gene  have  been
reported to be more susceptible to anti-SSA/Ro antibody-associated congenital hear block
[Clancy et al., 2003].
Systemic lupus erythematosus is a heterogeneous disease with diverse clinical manifestations
that range could be due to genetic factors. In this regard, we also analyzed the effect of the
-509C/T polymorphism in TGFB1 the clinical manifestations evolved in the course of the
disease [Manolova et al., 2012]. The results of our study demonstrated a weak association of
-509C/T polymorphism of TGFB1 with clinical manifestations of SLE. The carriage of the
heterozygous genotype was associated with about 2-fold higher risk for the occurrence of
hematological manifestations (OR=2.41; 95%CI: 1.10±5.32; p=0.016) and antibodies against
dsDNA (OR = 2.0; 95% CI: 0.96±4.2, p = 0.045) in lupus patients, while the CC genotype is a
protective factor for these events. Based on our and others data, we could assume the TGFβ1
gene polymorphisms as one of the genetic factors that explain the heterogeneity seen in SLE.
5. Conclusions
In recent years, efforts have been made to identify genes involved in the genetic predisposition
and severity of SLE. During the last two decades, many of the ‘candidate’ cytokine genes
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implicated in SLE development have been identified and was summarized in this review. SLE
is clinically heterogeneous and genetically complex, and we expect that individual genes and
cytokine patterns will be more or less important to different disease manifestations and
subgroups of patients. Defining these genotype-cytokine-phenotype relationships will
increase our understanding of both initial and progression disease pathogenesis.
In ours and others studies have been analyzed the association of IL-10 and TGF-β1genetic
variants with susceptibility to and outcome of SLE, showing variable results in most cases.
However, it is known that the actions of cytokines may be profoundly conditioned by the
presence of other cytokines, this being particularly true in the case of IL-10 and TGF-β1. New
studies of particular combinations of SNPs on these cytokine genes in individual genotype and
their impacts on the induced cytokine production could reveal the relation with susceptibility
and clinical presentation of autoimmunity diseases.
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